APGE — Apogee Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1974640 ·
Last close
$134.79
Market Cap
$8.38B
52W High
$134.88
52W Low
$75.86
ADV30
1,195,250
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -82,772,000 | -74,111,000 | 1,293,654,000 | 451,797,000 | 37,861,000 |
| Dec 2025 | 0 | — | -78,056,000 | -69,387,000 | 937,134,000 | 131,549,000 | 33,251,000 |
| Sep 2025 | 0 | — | -71,278,000 | -65,021,000 | 626,159,000 | 107,914,000 | 39,821,000 |
| Jun 2025 | 0 | — | -73,165,000 | -66,096,000 | 657,772,000 | 124,192,000 | 38,371,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-234,543,000
Investing CF
$-227,905,000
Financing CF
$807,035,000
CapEx
$-5,147,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-4.18
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-635,870,000
Inventory
—
Receivables
$7,281,000
ST Investments
$608,088,000
EBIT TTM
$-305,271,000
Pretax Income TTM
$-274,341,000
Interest Exp TTM
—
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -285,595,000 | -255,843,000 | 937,134,000 | 33,251,000 | — | -227,450,000 |
| Dec 2024 | 0 | -216,870,000 | -182,146,000 | 753,951,000 | 37,157,000 | — | -171,174,000 |
| Dec 2023 | 0 | -93,003,000 | -83,985,000 | 401,404,000 | 21,491,000 | — | -74,761,000 |
| Dec 2022 | 0 | -30,727,000 | -39,785,000 | 152,055,000 | 9,980,000 | — | -16,427,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-5.23
Max Pain — expiry 2026-09-18
max pain strike: $130.00 · spot: $134.79 · call oi: 4,208 · put oi: 3Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| QGEN | QIAGEN N.V. | $8.63B | $41.78 | — |
| IBRX | ImmunityBio, Inc. | $8.03B | $7.58 | — |
| TWST | Twist Bioscience Corp | $8.83B | $140.80 | — |
| IMVT | Immunovant, Inc. | $8.95B | $43.32 | — |
| PCVX | Vaxcyte, Inc. | $9.21B | $61.87 | — |
News headlines (Yahoo Finance, 1h cache)
Is Apogee Therapeutics (APGE) Fully Priced, Or Still A Bargain?
2026-08-03 19:08 · Yahoo
Baron Capital Exits Apogee Therapeutics (APGE) Following AbbVie Buyout
2026-08-05 12:17 · Yahoo
AbbVie Defends Its Turf, But Leaves One Big Question Open
2026-08-14 21:22 · Yahoo
Johnson & Johnson vs AbbVie: Safe Dividend vs Higher Yield
2026-08-12 18:30 · Yahoo
AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?
2026-08-11 11:05 · Yahoo
AbbVie Earnings Beat Forecasts as Skyrizi Sales Soar 24%. Why the Stock Is Falling.
2026-07-31 17:22 · Yahoo
AbbVie Trims Full-Year Profit Outlook Due to Apogee Acquisition
2026-07-31 15:45 · Yahoo
AbbVie Q2 2026 earnings: profit forecast cut for Apogee deal
2026-07-31 13:20 · Yahoo
Botox Maker Tops Buy Point, But Here Comes The Earnings Report
2026-07-28 18:40 · Yahoo
Is Apogee Therapeutics Inc. (APGE) Stock Outpacing Its Medical Peers This Year?
2026-07-28 13:40 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.